NASDAQ · IDXX
Healthcare · Medical - Diagnostics & Research
$554.99
Up+$9.91 (+1.82%)
Updated Aug 31, 2026, 9:39 AM
SID Score
4.6/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
IDXX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning IDXX.
IDXX research
Company profile and research snapshot.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | Barclays | Overweight | — |
| Aug 5, 2026 | UBS | Neutral | — |
| Aug 5, 2026 | Citigroup | Neutral | — |
| Jul 27, 2026 | UBS | Neutral | — |
| Apr 28, 2026 | UBS | Neutral | — |
No generated briefing is available yet.
Benzinga · Aug 25, 2026
In a new SEC filing on August 24, it was revealed that Emerson, EVP at IDEXX Laboratories (NASDAQ:IDXX), executed a significant exercise of company stock options. What Happened: A Form 4 filing with the U.S. Securities
Yahoo · Aug 21, 2026
IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.
Yahoo · Aug 20, 2026
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Focused Growth Fund”. A copy of the letter can be downloaded here. In the second quarter, the Baron Focused Growth Fund achieved a 13.26% gain, still trailing the Russell 2500 Growth Index’s 24.02% return. The underperformance was driven by ongoing concerns […]
SeekingAlpha · Aug 18, 2026
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day August 13, 2026 8:00 AM EDTCompany ParticipantsMichael Erickson - CEO, President & DirectorJulie...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IDXX.
